CEACAM5 and colorectal carcinoma: Considering the aforementioned studies focused on patients treated with anti-VEGF mAbs or chemotherapy alone, less is known about the role of CEA as a marker of CRC progression in patients who have undergone an anti-EGFR mAb combination regimen in real-world practice.